logo
Plus   Neg
Share
Email

Hormel Foods Trims FY19 Sales Outlook, Reaffirms EPS View - Quick Facts

While reporting financial results for the third quarter on Thursday, branded food company Hormel Foods Corp. (HRL) reaffirms its earnings guidance for the full-year 2019, while trimming annual net sales outlook as its navigates near-term uncertainty related to African swine fever.

For fiscal 2019, the company continues to project earnings in a range of $1.71 to $1.85 per share, while trimming annual net sales guidance to between $9.50 billion and $10.00 billion from the prior outlook range of $9.70 billion to $10.20 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.72 per share on net sales of $9.54 billion for the year. Analysts' estimates typically exclude special items.

"The fundamentals of our company are strong, and we remain focused on delivering our key results as we navigate near-term commodity market uncertainty," said Jim Snee, chairman of the board, president and chief executive officer of Hormel Foods.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT